Connection

Ivan Gentile to Alemtuzumab

Back to Details
This is a "connection" page, showing publications Ivan Gentile has written about Alemtuzumab.
Ivan Gentile
Connection Strength
0.865
Alemtuzumab
  1. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018 07; 17(7):709-717.
    View in: PubMed
    Score: 0.689
  2. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. Mult Scler Relat Disord. 2019 Jan; 27:44-45.
    View in: PubMed
    Score: 0.176
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.